Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00557375
Other study ID # MHIRB 2007-036
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 1, 2007
Est. completion date March 1, 2009

Study information

Verified date April 2022
Source Methodist Healthcare
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients with recent diagnosis and treatment of a brain tumor will complete a short questionnaire concerning the patient's quality of life and emotional state since receiving treatment. Caregivers will complete a one-page questionnaire concerning the patient's quality of life and emotional state since receiving treatment.


Description:

Patients with a recent diagnosis and treatment of a brain tumor (primary or metastatic; N=105, 61% female, 39% male) were identified in the clinics of Semmes-Murphey Neurologic and Spine Institute or the Methodist University Hospital in Memphis, TN. Caregivers were recruited from among relatives and friends who provide the most day-to-day care to the patient. All participants were between 3 months and 1 year from their most recent brain tumor treatment. Participants were given a simple, 5-point based survey to asses treatment-specific satisfaction, patient education, posttreatment quality of life, and pre- and post-treatment emotional impact. Therapeutic modalities surveyed include: surgery, external beam radiotherapy, whole-brain radiotherapy, stereotactic radiosurgery, and chemotherapy.


Recruitment information / eligibility

Status Completed
Enrollment 105
Est. completion date March 1, 2009
Est. primary completion date March 1, 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients who are between 3 months and one year out from treatment for their brain tumor - Karnofsky Performance Status (KPS) >= 60 - Age 18 years or over, any gender, any race - "patient caregivers will be individuals who provide the most day-to-day care for their respective brain tumor patients Exclusion Criteria: - No exclusions

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Methodist University Hospital Memphis Tennessee

Sponsors (1)

Lead Sponsor Collaborator
Methodist Healthcare

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall satisfaction and emotional impact of treatments in patients who have undergone therapy(s)for brain tumors. (greater than or equal to 3 months) from first treatment for brain tumor
Secondary Observational data about the treatment course and emotional well-being of the brain tumor patient as provided by the caregiver. (Greater than or equal to 3 months) from first treatment for brain tumor
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02846038 - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Completed NCT02537106 - A Comparison of the Effect of 1.5 Versus 3% NaCl on Brain Relaxation and Microcirculation N/A
Completed NCT01951950 - Nicardipine vs Esmolol Craniotomy Emergence Phase 1
Completed NCT01222780 - To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer Phase 1
Completed NCT00873184 - Study of Massage Therapy Within a Brain Tumor Setting N/A
Active, not recruiting NCT01115777 - Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies
Completed NCT00724191 - Evaluation of Human Brain Tumor Therapy Response by Magnetic Resonance (MR)
Completed NCT00003935 - Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma Phase 1
Recruiting NCT04128306 - Brain Areas of Time-To-Contact Perception: an Awake Surgery Study N/A
Recruiting NCT05202899 - Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniotomy Phase 4
Completed NCT00707343 - [F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors Phase 1
Completed NCT00850278 - Assessment of [18F]FLT-PET Imaging for Diagnosis and Prognosis of Brain Tumors N/A
Completed NCT00528437 - Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors Phase 2
Terminated NCT00107471 - Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma Phase 1/Phase 2
Completed NCT00187174 - Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors Phase 1
Completed NCT00135876 - Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients Phase 3
Completed NCT00062478 - Study of Karenitecin (BNP1350) in Patients With Brain Tumors Phase 2
Completed NCT00241670 - Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid Phase 3
Not yet recruiting NCT01445691 - More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery Phase 2
Terminated NCT01018290 - Navigated Transcranial Magnetic Stimulation in Tumor Surgery N/A